- Home
- TSHA vs DNA Comparison
TSHA vs DNA Comparison
Compare TSHA & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- DNA
- Stock Information
- Founded
- TSHA 2019
- DNA 2008
- Country
- TSHA United States
- DNA United States
- Employees
- TSHA N/A
- DNA N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSHA Health Care
- DNA Health Care
- Exchange
- TSHA Nasdaq
- DNA Nasdaq
- Market Cap
- TSHA 728.4M
- DNA 731.1M
- IPO Year
- TSHA 2020
- DNA N/A
- Fundamental
- Price
- TSHA $3.36
- DNA $11.15
- Analyst Decision
- TSHA Strong Buy
- DNA Hold
- Analyst Count
- TSHA 7
- DNA 2
- Target Price
- TSHA $8.71
- DNA $9.50
- AVG Volume (30 Days)
- TSHA 3.5M
- DNA 1.7M
- Earning Date
- TSHA 08-12-2025
- DNA 08-07-2025
- Dividend Yield
- TSHA N/A
- DNA N/A
- EPS Growth
- TSHA N/A
- DNA N/A
- EPS
- TSHA N/A
- DNA N/A
- Revenue
- TSHA $8,098,000.00
- DNA $230,815,000.00
- Revenue This Year
- TSHA N/A
- DNA N/A
- Revenue Next Year
- TSHA N/A
- DNA $13.73
- P/E Ratio
- TSHA N/A
- DNA N/A
- Revenue Growth
- TSHA N/A
- DNA 25.21
- 52 Week Low
- TSHA $1.05
- DNA $5.00
- 52 Week High
- TSHA $3.40
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- TSHA 70.13
- DNA 44.28
- Support Level
- TSHA $2.79
- DNA $10.95
- Resistance Level
- TSHA $2.99
- DNA $11.97
- Average True Range (ATR)
- TSHA 0.16
- DNA 0.99
- MACD
- TSHA 0.03
- DNA -0.20
- Stochastic Oscillator
- TSHA 93.71
- DNA 17.02
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.